A Phase 4 interventional study of Magnesium Sulfate and Lidocaine in Anesthesia and Pain, sponsored by Brasilia University Hospital. Completed at 1 site in Brazil. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2020-02-27.
Sponsored by Brasilia University Hospital · Phase 4, Interventional, and Supportive care
This study evaluates the addition of continuous infusion of lidocaine or continuous infusion of magnesium sufate in the duration of spinal anesthesia.
Both lidocaine and magnesium sulfate have been shown to prolong spinal anesthesia.
The number of studies using magnesium sulfate to improve spinal anesthesia is greater than the number of studies using lidocaine, and methodology varies significantly between studies.
Adverse effects of lidocaine are different from magnesium sulfate's. Lidocaine has a wider therapeutic interval with fewer side effects, including: Drowsiness, Feeling Anxious, Feeling Cold, Nervous, Numbness And Tingling, Signs And Symptoms At Injection Site, Twitching.
Magnesium sulfate's side effects include: heart disturbances, breathing difficulties, poor reflexes, confusion, weakness, flushing (warmth, redness, or tingly feeling), sweating, lowered blood pressure, feeling like you might pass out, anxiety, cold feeling, extreme drowsiness, muscle tightness or contraction, or headache.
10,054 studies on the registry are indexed under Pain; 1,649 are open to participants now.
This study's enrollment of 44 is below the median of 66 across 8,493 interventional studies indexed under Pain.
Browse Pain studies →Brasilia University Hospital is the lead sponsor of 20 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Continuous intravenous infusion of 15mg/kg/h of magnesium sulfate, starting just after spinal anesthesia infusion until the end of surgery
Drug: Magnesium Sulfate
Continuous intravenous infusion of 1.5mg/kg/h of lidocaine, starting just after spinal anesthesia infusion until the end of surgery
Drug: Lidocaine
Magnesium Sulfate 15mg/kg/h
Lidocaine 1,5mg/kg/h
Sensitive block duration
Thermal and pinprick level lowering to S2
Time frame: 9 hours
Motor block duration
Time to Bromage return to baseline
Time frame: 9 hours
Two levels regression
Time from maximal thermal (cold) sensitive block level to lower two levels
Time frame: 9 hours
Pain at postanesthesia care unit
Maximum pain (0-10 verbal scale) during PACU
Time frame: 1-3 hours
Plan to share: Yes — We plan to share de-identified IPD in Mendeley Data after study completion
Supporting information: Analytic code
Time frame: Analystic code will be published in RPUBS
Access criteria: Open Access
No publications or documents are linked to this record.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lidocaine
Brasilia University Hospital